Treatment adherence
PrEP adherence in Partners PrEP
Open access · cc by · source: Europe PMC
In a Partners PrEP adherence substudy, median pill-count and MEMS adherence exceeded 97%, and counseling restored most low adherers to ≥80%.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Median adherence 99.1% (UPC) and 97.2% (MEMS); few had sustained low UPC adherence; among those triggered, 92% returned to ≥80% UPC after intervention sessions.
Evidence for the claim as stated.
At three Partners PrEP sites, 1,147 HIV-uninfected partners had unannounced pill counts and MEMS monitoring, with stepped counselling when UPC adherence fell below 80%. Median adherence was 99.1% (UPC) and 97.2% (MEMS); among those triggered, 92% returned to ≥80% UPC after sessions. Those figures describe intensively monitored trial adherence, including in a placebo-controlled parent study, not routine-clinic PrEP taking.
Evidence for the claim as stated.
Who is blinded, and whether a placebo exists, disagrees across the four papers. SEPP blinded the collector while comparing an identifiable parenting programme with standard care. Partners PrEP adherence work sits inside a placebo-controlled antiretroviral trial but reports UPC/MEMS adherence (99.1%/97.2%), not a placebo-subtracted efficacy estimate. The child-care zBMI trial is an open cluster-style programme contrast. FibriCheck does not assign a treatment at all. One method label is doing four jobs.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Who is blinded, and whether a placebo exists, disagrees across the four papers. SEPP blinded the collector while comparing an identifiable parenting programme with standard care. Partners PrEP adherence work sits inside a placebo-controlled antiretroviral trial but reports UPC/MEMS adherence (99.1%/97.2%), not a placebo-subtracted efficacy estimate. The child-care zBMI trial is an open cluster-style programme contrast. FibriCheck does not assign a treatment at all. One method label is doing four jobs.
- Supports · Tech parenting program cut postpartum distress
- Supports · Child-care diet/activity RCT and zBMI
- Supports · Smartphone PPG to detect atrial fibrillation
Study at a glance
- Design
- Cohort — Partners PrEP adherence substudy with UPC, MEMS, and stepped counseling
- N
- N=1147 · HIV-uninfected partners at three East African sites
- Population
- HIV-uninfected partners in serodiscordant couples on PrEP within a clinical trial
- Outcome
- Pill-count and MEMS adherence, and return to ≥80% after counseling
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
PrEP adherence in Partners PrEP
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
1,147 participants enrolled in the adherence substudy.
1,147 participants were enrolled in the study, reflecting 66% of all participants in the three study sites.
Median adherence 99.1% by UPC and 97.2% by MEMS.
Median overall participant adherence was 99.1% (IQR 96.9%–100%) by UPC and 97.2% (IQR 90.6%–100%) by MEMS.
Key findings
Median adherence 99.1% (UPC) and 97.2% (MEMS); few had sustained low UPC adherence; among those triggered, 92% returned to ≥80% UPC after intervention sessions.
Methodology
At three Partners PrEP sites, 1,147 HIV-uninfected partners received unannounced pill counts (UPC) and MEMS monitoring plus stepped adherence counseling when UPC fell below 80%.
Limitations
High adherence in a trial with intensive monitoring may not equal routine clinic PrEP adherence.
Related papers in this topic
Same topic cluster — not a recommendation engine.